Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 7,091,548	$ 8,446,158
Contracts and grants receivable	117,029
Unbilled revenue		171,254
Research and development incentives receivable, current	25,253	23,894
Deferred issuance cost	132,681
Prepaid expenses and other current assets	451,876	866,014
Total current assets	7,818,387	9,507,320
Security deposit	22,777	22,777
Office furniture and equipment, net	10,339	11,927
Right-of-use lease assets	200,569	229,834
Research and development incentives receivable, net of current portion	6,313	25,468
Total assets	8,058,385	9,797,326
Current liabilities:
Accounts payable	1,436,728	1,111,226
Accrued expenses	2,602,665	2,418,002
Accrued compensation	50,216	251,115
Lease liabilities, current	125,143	121,765
Convertible debt	2,996,136	2,250,000
Total current liabilities	7,210,888	6,152,108
Non-current liabilities:
Convertible debt		1,010,934
Lease liabilities, net of current portion	79,125	111,862
Total liabilities	7,290,013	7,274,904
Commitments and contingencies (Note 6)
Shareholders' equity:
Preferred stock, 350,000 shares authorized; none issued or outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Common stock, $.001 par value; 75,000,000 shares authorized; 10,524,437 and 10,378,238 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	10,524	10,378
Additional paid-in capital	228,353,208	228,193,977
Accumulated other comprehensive income	24,143	22,243
Accumulated deficit	(227,619,503)	(225,704,176)
Total shareholders' equity	768,372	2,522,422
Total liabilities and shareholders' equity	$ 8,058,385	$ 9,797,326